Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 181-187

  Kajinami, Kouji ^a   Nishitsuji, Masaru ^a   Takeda, Yasuo ^a   Shimizu, Masami ^a   Koizumi, Junji ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Coronary atherosclerosis; Familial hypercholesterolemia; Probucol; Xanthoma

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROBUCOL; TRIACYLGLYCEROL;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; CASE REPORT; CORONARY ARTERY ATHEROSCLEROSIS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; MALE; PRIORITY JOURNAL; XANTHOMA;

EID: 0030054090     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05699-8     Document Type: Article

References (22)

1. The Expert Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015.
2. Pyörälä K, Backer GD, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110:121.
3. Heel RC, Brogden RN, Speight TM, Avery GS. Probucol: A review of its pharmacological properties and therapeutic use in patients with hypercholesterolemia. Drugs 1978;15:409.
4. Kesäniemi YA, Grundy SM. Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res 1984;25:780.
5. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtoi CR. Mechanism of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989;9:462.
6. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H.
7. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
8. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725.
9. Mabuchi H, Ito S, Haba T, et al. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis 1977;28:61.
10. Mabuchi H, Kamon N, Fujita H et al. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism 1987;36:475.
11. Mabuchi H, Tatami R, Haba T et al. Achilles' tendon thickness and ischemic heart disease in familial hypercholesterolemia. Metabolism 1987;27:1672.
12. Davignon J, Nestruck AC, Alaupovic P, Bouthillier D. Severe hypoalphalipoprotein induced by a combination of probucol and clofibrate. In: Angel A and Frohlich J. (eds.), Lipoprotein Deficiency Syndromes: Advances in Experimental Medicine and Biology, Vol. 201, Plenum Press, New York, 1986, p. 111.
13. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379.
14. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982;257:6653.
15. Tatami R, Mabuchi H, Ueda K et al. Intermediate density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174.
16. Jagannathan SN, Connor WE, Baker WH et al. The turnover of cholesterol in human atherosclerotic arteries. J Clin Invest 1974;54:366.
17. Bhattacharyya AK, Connor WE, Mausolf FA, Flatt AE. Turnover of xanthoma cholesterol in hyperlipoproteinemia patients. J Lab Clin Med 1976;87:503.
18. Illingworth DR, Cope R, Bacon SP. Regression of tendon xanthomas in patients with familial hypercholesterolemia treated wtih lovastatin. South Med J 1990;83:1053.
19. Kragel AH, Roberts WC. Composition of atherosclerotic plaques in the coronary arteries in homozygous familial hypercholesterolemia. Am Heart J 1991;121:210.
20. McLean LR, Thomas CE, Weintraub B, Hagaman KA. Modulation of the physical state of cellular cholesteryl esters by 4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol). J Biol Chem 1992;267:12291.
21. Wissler RW, Vesselinovitch D. Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkeys aortas. Appl Pathol 1983;1:89.
22. Walldius G, Erikson U, Olsson AG et al. The effects of probucol on femoral atherosclerosis: The probucol quantitative regression Swedish trial (PQRST). Am J Cardiol 1994;74:875.